HDAC9抑制作为一种新的中风治疗方法
1Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, United Kingdom.
Stroke
|November 9, 2023
概括
HDAC9的一个遗传变体 (基因组脱乙酶9) 与动脉样硬化性中风和心脏病有关. 抑制HDAC9显示为心血管疾病的新疗法战略.
科学领域:
- 遗传学 遗传学 是一个
- 心血管医学 心血管医学
- 分子生物学分子生物学
背景情况:
- 鉴定出HDAC9基因的一个变体是大动脉动脉硬化性中风和冠状动脉疾病的危险因素.
- 在人类动脉样硬化斑块中,HDAC9的表达升高,这表明它在疾病发病过程中起作用.
- 在临床前模型中降低HDAC9蛋白水平与降低动脉样硬化疾病负担有关.
研究的目的:
- 探索从HDAC9基因发现到动脉样硬化疾病的新型治疗方法的途径.
- 研究HDAC9抑制作为动脉样硬化心血管疾病治疗策略的潜力.
主要方法:
- 对识别HDAC9变异的遗传关联研究的审查.
- 对研究HDAC9功能和抑制的临床前研究 (动物和细胞模型) 的分析.
- 检查与HDAC9抑制相关的流行病学数据和临床试验信息.
主要成果:
- 鉴定出HDAC9基因变异为动脉样性中风和冠状动脉疾病的危险因素.
- 临床前研究表明,降低HDAC9水平可以减轻动脉样硬化.
- 酸是一种非特异性HDAC抑制剂,显示了临床前的有效性和流行病学相关性,减少了心血管事件.
结论:
- 抑制HDAC9代表了动脉样硬化心血管疾病的一个有前途的新型治疗标.
- 目前正在进行临床试验,以评估HDAC9抑制剂用于治疗大动脉中风.
- 针对更广泛的心血管应用,正在进一步开发特定的HDAC9抑制剂.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:22Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197